Preview Mode Links will not work in preview mode

Jun 2, 2022

May was Bladder Cancer Awareness Month, so we wanted to share a conversation with Dr. Yair Lotan on the state of bladder cancer awareness and research, his work with the Bladder Cancer Advocacy Network, and some of the advancements in bladder cancer research that most excite him.

Dr. Lotan is a urology professor and chief of urologic oncology at University of Texas Southwestern Medical Center in Dallas, Texas. He’s known nationally for his research on urine markers and molecular markers, which will help determine patients at higher risk for recurrent cancer. 

Bladder cancer is the sixth most common cancer diagnosed annually in the U.S., according to the National Library of Medicine.

This is the second part of a two-part conversation we conducted with Dr. Lotan. In the first, we discussed a micro-cost analysis published in Urology that broke down per-procedural costs for cystoscopy and explored how single-use cystoscopes might provide a cost-effective option for providers.

Dr. Lotan is an Ambu consultant.

Show notes: